Peginterferon alfa-2a (40 kDa) monotherapy: a novel agent for chronic hepatitis C therapy

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

2001 • 6,133 citations

Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C

1998 • 3,550 citations

The Prevalence of Hepatitis C Virus Infection in the United States, 1988 through 1994

1999 • 3,083 citations

Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus

1998 • 2,374 citations

Peginterferon Alfa-2a in Patients with Chronic Hepatitis C

2000 • 1,246 citations

Epidemiology of hepatitis C

1997 • 1,112 citations

The Treatment of Chronic Viral Hepatitis

1997 • 974 citations

Peginterferon Alfa-2a in Patients with Chronic Hepatitis C and Cirrhosis

2000 • 893 citations

Treatment of Acute Hepatitis C with Interferon Alfa-2b

2001 • 818 citations

A Randomized, Double–Blind Trial Comparing Pegylated Interferon Alfa–2B to Interferon Alfa–2B As Initial Treatment for Chronic Hepatitis C

2001 • 683 citations

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration

1996 • 675 citations

Rational Design of a Potent, Long-Lasting Form of Interferon: A 40 kDa Branched Polyethylene Glycol-Conjugated Interferon α-2a for the Treatment of Hepatitis C

2001 • 605 citations

National Institutes of Health Consensus Development Conference Panel statement: Management of hepatitis C

1997 • 572 citations

Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis

1991 • 542 citations

Pegylated interferon-α2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data

2000 • 513 citations

The uses and properties of PEG-linked proteins.

1992 • 425 citations

Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial

1997 • 384 citations

Efficacy and safety of pegylated (40-kd) interferon α-2a compared with interferon α-2a in noncirrhotic patients with chronic hepatitis C

2001 • 370 citations

High Rate of Infectivity and Liver Disease in Blood Donors with Antibodies to Hepatitis C Virus

1991 • 290 citations

Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon α2a

2001 • 276 citations

Volunteer Blood Donors with Antibody to Hepatitis C Virus: Clinical, Biochemical, Virologic, and Histologic Features

1995 • 264 citations

Therapy of hepatitis C: Meta-analysis of interferon alfa-2b trials

1997 • 259 citations

A Branched Monomethoxypoly(ethylene glycol) for Protein Modification

1995 • 252 citations

Clinical Pharmacokinetics of Interferons

1990 • 245 citations

Polyethylene glycol-conjugated pharmaceutical proteins

1998 • 240 citations

Short Communication: Renal Tubular Vacuolation in Animals Treated with Polyethylene-Glycol-Conjugated Proteins

1998 • 236 citations

Treatment of hepatitis C virus-related cirrhosis: A randomized, controlled trial of interferon alfa-2b versus no treatment

1999 • 219 citations

Short Communication: Renal Tubular Vacuolation in Animals Treated with Polyethylene-Glycol-Conjugated Proteins

1998 • 214 citations

Pathogenesis, diagnosis and management of hepatitis C

2000 • 191 citations

Hepatitis C

1996 • 156 citations

Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: Analysis of individual patient data of six controlled trials

1999 • 155 citations

Interferon kinetics and adverse reactions after intravenous, intramuscular, and subcutaneous injection

1984 • 116 citations

Pegylated (40kDa) interferon alfa-2a (PEGASYS®) in combination with ribavirin: Efficacy and safety results from a phase III, randomized, actively-controlled, multicenter study

2001 • 109 citations

Outcome of acute symptomatic non‐A, non‐B hepatitis: a 13‐year follow‐up study of hepatitis C virus markers

1993 • 108 citations

Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjects

1996 • 83 citations

Efficacy of interferon treatment for patients with chronic hepatitis C: Comparison of response in cirrhotics, fibrotics, or nonfibrotics

1999 • 67 citations

Current therapy for chronic hepatitis C

2000 • 63 citations

Biopharmaceutical Properties of Uricase Conjugated to Neutral and Amphiphilic Polymers

1999 • 60 citations

Chronic non‐A, non‐B hepatitis developed after transfusions, illicit self‐injections or sporadically. Outcome during long‐term follow‐up – a comparison

1989 • 52 citations

Hepatitis C: Natural History of a Unique Infection

1995 • 51 citations

A pharmacokinetic model for alpha interferon administered subcutaneously

1999 • 49 citations

Non-A, non-B posttransfusion hepatitis: Comparing C and non-C hepatitis

1993 • 49 citations

Pegylated (40kDa) interferon alfa-2a (PEGASYS®) in combination with ribavirin: Efficacy and safety results from a phase III, randomized, actively-controlled, multicenter study

2001 • 46 citations

CARDIOVASCULAR PHARMACOLOGY OF AGING

1999 • 41 citations

Interspecies Scaling of Interferon Disposition and Comparison of Allometric Scaling with Concentration-Time Transformations

1995 • 40 citations

Time Course of Interferon Levels, Antiviral State, 2′,5′-Oligoadenylate Synthetase and Side Effects in Healthy Men

1987 • 34 citations

Prospective study of interferon therapy for compensated cirrhotic patients with chronic hepatitis C by monitoring serum hepatitis C RNA

1999 • 33 citations

Pegylated interferon alfa-2a (PEGASYSTM) and ribavirin combination therapy for chronic hepatitis C: A phase II open-label study

2000 • 19 citations

Long‐term follow‐up of anti‐hepatitis C virus antibodies in patients with acute nonA nonB hepatitis and different outcome of liver disease

1992 • 18 citations

Adherence to therapy enhances sustained response in chronic hepatitis C patients receiving PEG-interferon alfa-2b plus ribavirin

2001 • 18 citations

Is antiviral treatment (IFN alpha and/or ribavirin) justified in cirrhosis related to hepatitis C virus? Société Royale Belge de Gastro-entérologie.

1999 • 15 citations

Efficacy of high dose of recombinant alpha 2b interferon on long term response in chronic hepatitis C and cirrhosis: prospective randomized multicentre study.

1998 • 12 citations

Diagnosis and Treatment of the Major Hepatotropic Viruses

1993 • 8 citations

Design of the halt-C trial (Hepatitis C antiviral long-term treatment to prevent Cirrhosis)

2000 • 7 citations